Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Common Stock?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1997 - 2021 (25 years)

Common Stock is 
0.0 (1Y - )

ALXN Stock Price & Common Stock

Common Stock for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Common Stock

chevron_right 2021 0.0 -1.0x
( -100.0% / year avg)
chevron_left 1997 $86.1M
vertical_align_top Peak $86.1M -
vertical_align_bottom Bottom 0.0
arrow_drop_up # Up Years 11 11 of 25
years up.
arrow_drop_down # Down Years 4
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1997 , or -45.0x faster than it's common stock over the same period.
  • If ALXN shrinks it's stock at the same rate as it's common stock (-100.0%/year) , it's stock price will shrink 0% and hit $0.0 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 11 years (0%) it's common stock were also up.
  • ALXN Historical Common Stock Table
    in $ million
    Year Common Stock YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $0 - - -
    4/1/2020 $0 - - -
    4/1/2019 $0 - - -
    4/1/2018 $0 -100.0% - -
    4/1/2017 $0 -33.3% - -
    4/1/2016 $0 -19.8% - -
    4/1/2015 $0 7.5% - -
    4/1/2014 $0 0.0% - -
    4/1/2013 $0 5.3% - -
    4/1/2012 $0 55.1% - -
    4/1/2011 $0 145.0% - -
    4/1/2010 $0 0.0% - -
    4/1/2009 $0 0.0% - -
    4/1/2008 $0 25.0% - -
    4/1/2007 $0 33.3% - -
    4/1/2006 $0 0.0% - -
    4/1/2005 $0 20.0% - -
    4/1/2004 $0 25.0% - -
    4/1/2003 $0 0.0% - -
    4/1/2002 $0 0.0% - -
    4/1/2001 $0 33.3% - -
    4/1/2000 $0 - - -
    4/1/1999 $0 - - -
    4/1/1998 $0 -100.0% - -
    4/1/1997 $86 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Common stock is a security that represents ownership in a corporation. Holders of common stock elect the board of directors and vote on corporate policies. This form of equity ownership typically yields higher rates of return long term. However, in the event of liquidation, common shareholders have rights to a company's assets only after bondholders, preferred shareholders, and other debtholders are paid in full. Common stock is reported in the stockholder's equity section of a company's balance sheet.

    For more detailed definitions, please see Investopedia.